Novel and costly therapies are available, such as PCSK9 inhibitors, [39] and new antithrombotic treatment schemes, such as dual antiplatelet therapy or adding rivaroxaban to aspirin (dual pathway inhibition), [40] aiming to reduce cardiovascular disease risk. This evidence concerns the gene PCSK9 and cardiovascular disorder.